ShockWave Medical, Inc. (SWAV)
NASDAQ: SWAV · IEX Real-Time Price · USD
325.63
+3.02 (0.94%)
At close: Mar 28, 2024, 4:00 PM
330.00
+4.37 (1.34%)
After-hours: Mar 28, 2024, 7:56 PM EDT
ShockWave Medical Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for ShockWave Medical stock have an average target of 260.08, with a low estimate of 165 and a high estimate of 310. The average target predicts a decrease of -20.13% from the current stock price of 325.63.
Analyst Consensus: Buy
* Price targets were last updated on Feb 16, 2024.
Analyst Ratings
The average analyst rating for SWAV stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
Buy | 4 | 4 | 3 | 3 | 3 | 3 |
Hold | 3 | 3 | 3 | 3 | 3 | 3 |
Sell | 1 | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 13 | 13 | 12 | 12 | 12 | 12 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Wells Fargo | Wells Fargo | Hold Maintains $200 → $210 | Hold | Maintains | $200 → $210 | -35.51% | Feb 16, 2024 |
Piper Sandler | Piper Sandler | Buy Maintains $275 → $290 | Buy | Maintains | $275 → $290 | -10.94% | Feb 16, 2024 |
Needham | Needham | Strong Buy Maintains $260 → $286 | Strong Buy | Maintains | $260 → $286 | -12.17% | Feb 16, 2024 |
Morgan Stanley | Morgan Stanley | Buy Maintains $284 → $223 | Buy | Maintains | $284 → $223 | -31.52% | Dec 4, 2023 |
Morgan Stanley | Morgan Stanley | Buy Maintains $313 → $284 | Buy | Maintains | $313 → $284 | -12.78% | Nov 7, 2023 |
Financial Forecast
Revenue This Year
939.11M
from 730.23M
Increased by 28.60%
Revenue Next Year
1.15B
from 939.11M
Increased by 22.78%
EPS This Year
4.94
from 3.85
Increased by 28.31%
EPS Next Year
6.24
from 4.94
Increased by 26.36%
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 971.3M | 1.2B | 1.5B | 1.8B | 1.9B |
Avg | 939.1M | 1.2B | 1.4B | 1.6B | 1.9B |
Low | 899.1M | 1.1B | 1.2B | 1.4B | 1.8B |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 33.0% | 31.3% | 31.0% | 32.6% | 21.0% |
Avg | 28.6% | 22.8% | 19.9% | 14.9% | 17.5% |
Low | 23.1% | 12.9% | 4.9% | -0.7% | 12.9% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|
High | 6.55 | 7.62 | 8.88 | 9.90 |
Avg | 4.94 | 6.24 | 7.57 | 8.54 |
Low | 3.91 | 5.05 | 6.23 | 6.83 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|
High | 70.2% | 54.3% | 42.3% | 30.7% |
Avg | 28.3% | 26.4% | 21.3% | 12.7% |
Low | 1.6% | 2.2% | -0.1% | -9.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.